Product news from the 1/23/07 news brief

Share this article:
The FDA has approved Shire’s Lialda (mesalamine) indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Lialda is the first and only FDA-approved once-daily oral formulation of mesalamine. Shire will launch Lialda in the US during the first quarter of 2007. Stiefel Laboratories received FDA approval for Olux-E (clobetasol propionate) foam, indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, also known as psoriasis and eczema, in patients 12 years of age or older. Steifel said Olux-E is will be available in U.S. pharmacies by March 2007 in 50 g and 100 g canisters.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.